Clinical Trial

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

Name: FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms — clinical trial record (NCT06858618)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase 2, open-label, multicenter study to safety \& tolerability, antitumor activity, and pharmacokinetics of FCN-338 in Combination with szacitidine (AZA) or chemotherapy(erythromycin, cytarabine(Ara-C)) in Patients with myeloid neoplasms

Trial Details

NCT Number	NCT06858618
Lead Sponsor	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Collaborators: Beijing Fosun Pharmaceutical Technology Development Co., Ltd.
Conditions	Safety, Antitumor Activity, PK Profile
Enrollment	47 participants
Start Date	2023-08-16
Primary Completion	2026-12-01 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-05